Elutia (NASDAQ:ELUT) PT Raised to $10.00

Elutia (NASDAQ:ELUTFree Report) had its price objective hoisted by Lake Street Capital from $5.00 to $10.00 in a report issued on Friday morning, Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

Separately, Cantor Fitzgerald lifted their price objective on Elutia from $5.00 to $11.00 and gave the stock an overweight rating in a research note on Tuesday, June 18th.

Check Out Our Latest Report on ELUT

Elutia Trading Up 11.7 %

NASDAQ:ELUT opened at $3.91 on Friday. The stock has a 50-day moving average price of $3.22 and a 200 day moving average price of $3.17. The stock has a market capitalization of $94.90 million, a P/E ratio of -1.65 and a beta of 0.61. Elutia has a 12-month low of $1.10 and a 12-month high of $4.39.

Elutia (NASDAQ:ELUTGet Free Report) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.75) earnings per share (EPS) for the quarter. The firm had revenue of $6.69 million for the quarter. On average, research analysts predict that Elutia will post -1.38 earnings per share for the current fiscal year.

Institutional Trading of Elutia

A hedge fund recently bought a new stake in Elutia stock. Perkins Capital Management Inc. acquired a new position in shares of Elutia Inc. (NASDAQ:ELUTFree Report) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 797,602 shares of the company’s stock, valued at approximately $2,512,000. Elutia comprises about 2.1% of Perkins Capital Management Inc.’s portfolio, making the stock its 12th biggest position. Perkins Capital Management Inc. owned about 3.29% of Elutia as of its most recent SEC filing. Hedge funds and other institutional investors own 74.03% of the company’s stock.

Elutia Company Profile

(Get Free Report)

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.

Featured Articles

Receive News & Ratings for Elutia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elutia and related companies with MarketBeat.com's FREE daily email newsletter.